Design Therapeutics, Inc. Profile Avatar - Palmy Investing

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia…

Biotechnology
US, Carlsbad [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group

Peers Performance

A quick analysis that compared Design Therapeutics, Inc. (DSGN) to it's peer group.

Peer Group
Loading...
End of DSGN's Analysis
CIK: 1807120 CUSIP: 25056L103 ISIN: US25056L1035 LEI: - UEI: -
Secondary Listings
DSGN has no secondary listings inside our databases.